The United Kingdom’s medicines regulator has authorized clinical trials for a novel Ebola vaccine developed by researchers at the University of Oxford. The vaccine entered human testing following a public health emergency declaration on 17 May, with development beginning at that time. This marks the first of four vaccines under development to advance to clinical trial stages.
The current Ebola outbreak, primarily affecting the Democratic Republic of the Congo, has resulted in 625 deaths among 1,792 laboratory-confirmed cases. The outbreak involves the Bundibugyo species of Ebola, which has triggered two previous outbreaks. Because the six known Ebola species require distinct treatments and vaccines, no approved therapeutics currently exist for this particular variant. Researchers note that the epidemic remains uncontrolled and is occurring in a conflict zone with highly mobile populations, factors that underscore the urgency for vaccine development.
The trial will involve 50 healthy adults aged 18-55 in the UK, with initial doses expected to be administered within weeks of the approval. Researchers are simultaneously preparing for trials in Uganda in collaboration with regional partners. The vaccine uses a modified chimpanzee cold virus as a vector, a technology that gained prominence during coronavirus vaccine development. Scientists insert genetic material from the Bundibugyo Ebola virus into this harmless carrier, prompting the immune system to recognize and prepare a response without causing actual infection. The Serum Institute of India has manufactured and stockpiled approximately 620,000 doses.
Unlike typical vaccine development timelines spanning up to a decade, researchers compressed this process by conducting testing phases in parallel rather than sequentially. The accelerated approach maintains standard safety and efficacy protocols while allowing multiple teams to work simultaneously across different locations. Scientists note that while the platform technology demonstrated rare blood clots in some recipients during previous use, affecting up to one in 100,000 people, the threat from Bundibugyo Ebola—which is fatal in approximately one-third of infections—represents a significantly greater risk.
Three additional vaccine candidates remain under development by other organizations, including Moderna’s messenger RNA-based approach and variants utilizing proven techniques from other Ebola species. Trial volunteers will be monitored for one year, though researchers anticipate obtaining early data on immune response and potential side effects within a shorter timeframe.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI